PLD Combined With Cisplatin in the Treatment of Advanced Poorly Differentiated Thyroid Carcinoma

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.30 enrolled

Overview

This is a prospective, multicenter, open label Phase II Clinical Trial. 30 advanced poorly differentiated thyroid carcinoma patients who were histopathologically confirmed inoperable were enrolled in this study.

Subjects will receive the treatment regimen as follow: intravenous infusion of liposomal doxorubicin 35 mg/m2, d1; cisplatin 75 mg/m2, drip, total dose should be carried out on d1-3; once every 21days, for 6 cycles. Stop the treatment if the patients have progressed or intolerated to the toxicity. The primary endpoint is disease control rate(DCR), the secondary endpoint is overall survival (OS), progression-free survival (PFS), safety and quality of life assessment(QoL).

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Poorly Differentiated Thyroid Carcinoma

Interventions

PLDDRUG

intravenous infusion of liposomal doxorubicin 35 mg/m2, d1,once every 21days, for 6 cycles.

CisplatinDRUG

cisplatin 75 mg/m2, drip, total dose should be carried out on d1-3; once every 21days, for 6 cycles.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Volunteer to participate and sign the informed consent form; 2. Age :18-70 years old; 3. Histopathologically confirmed inoperable advanced poorly differentiated thyroid carcinoma; 4. Previously received surgery, I131 treatment, radiotherapy, chemotherapy patients can be enrolled； 5. At least one measurable lesion according to the solid tumor efficacy evaluation criteria (RECIST 1.1); 6. Expected survival time ≥ 3 months; 7. Karnofsky score ≥70; 8. Blood test：ANC ≥1.5×109/L； PLT ≥75×109/L；Hb ≥90g/L; 9. Liver function:Serum bilirubin (SB) level:≤ normal upper limit（ULN）2 times; aspartate aminotransferase(AST) and alanine aminotransferase(ALT) ≤ ULN 2.5times; or ≤ ULN 5times if Liver metastases are present; 10. Renal function: Serum creatinine ≤ ULN 1.5times; 11. LVEF ≥ 50%; 12. No serious complications such as active digestive tract hemorrhage, perforation, jaundice, gastrointestinal obstruction, noncancerous fever \> 38℃; 13. Subjects are well-behaved, able to undergo the follow-up efficacy and adverse reactions according to the program requirements. Exclusion Criteria: 1. Active or uncontrolled severe infection (≥CTCAE grade 2 infection)； 2. Previously received anthracycline-based regimen: the cumulative dose of doxorubicin at or above 500 mg / m2 or the cumulative dose of epirubicin reached or exceeded 800 mg / m2; 3. The New York Heart Association (NYHA) graded class II or above heart disease patients previously or at present; 4. Patients with CNS disorders or CNS metastases; 5. Allergic to chemotherapeutic drugs or their excipients or intolerant patients; 6. Received any other test drug treatment within 30 days of the first chemotherapy administration; 7. Pregnant or lactating women; 8. Arterial/venous thrombosis occurred within 6 months, such as cerebrovascular accident (including transient ischemic attack), deep venous thrombosis, and pulmonary embolism; 9. History of aneurysm; 10. Neurological disorders with a history of epilepsy or ataxia require treatment; 11. A history of drug abuse and incapable of abstinence or mental disorder; 12. A history of peripheral neuropathy and the muscle strength is below level 3; 13. Suffering from other diseases and complications of hand-foot syndrome; 14. Researchers think it is not suitable for enrolling.

Locations (1)

Zhejiang Cancer Hospital

Zhejiang, China

RECRUITING

Outcomes

Primary Outcomes

disease control rate(DCR)

the rate of CR,PR and SD

Time frame: disease control rate will be evaluated every 2 cycles (each cycle is 21 days) from date of administration of drugs until the date of first documented progression，up to 18 months.

Secondary Outcomes

overall survival

Time frame: From date of randomization until the date of death from any cause,assessed up to 18 months.

PFS

progression-free survival

Time frame: From date of randomization until the date of first documented disease progression or date of death from any case,whichever came first,assessed up to 18 months.

Incidence of adverse events assessed by number and severity of adverse event in the treatment.

Evaluate the adverse reaction rate of drugs assessed by number and severity of adverse events in the treatment of advanced thyroid poorly differentiated carcinoma.

Time frame: A summary of adverse events of each cycle,from date of administration of drugs until 30 days after the last chemotherapy or progression,whichever came first,assessed up to 18 months.

quality of life assessment

Evaluate the QoL according to Functional Assessment of Cancer Therapy.

Time frame: It will be assessed before the administration of drugs at each first day of the chemotherapy cycle,up to 6 cycles,each cycle is 21 days.

Central Contacts

jiandong nie, doctor

CONTACT

0311-66575708 niejd@mail.ecspc.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.